Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Per Olov Hedlund, Martti Ala-Opas, Einar Brekkan, Jan Erik Damber, Lena Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Ake Pousette, Finn Rasmussen, Jaakko Salo, Sigmund Vaage, Eberhard Varenhorst, Scandinavian Prostatic Cancer Group

    47 Citationer (Scopus)

    Abstrakt

    In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.
    OriginalsprogEngelsk
    TidsskriftScandinavian Journal of Urology and Nephrology
    Vol/bind36
    Udgave nummer6
    Sider (fra-til)405-13
    Antal sider9
    ISSN0036-5599
    DOI
    StatusUdgivet - 1 jan. 2002

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5'. Sammen danner de et unikt fingeraftryk.

    Citationsformater